REFERENCIAS BIBLIOGRÁFICAS

Geske JB, Ommen SR, Gersh BJ. Hypertrophic Cardiomyopathy: Clinical Update. JACC Hear Fail [Internet]. 2018;6(5):364–75. Available from: doi:10.1016/j.jchf.2018.02.010

Zegkos T, Tziomalos G, Parcharidou D, Ntelios D, Papanastasiou CA, Karagiannidis E, et al. Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with Hypertrophic Cardiomyopathy. Hell J Cardiol [Internet]. 2022;63:15–21. Available from: doi:10.1016/j.hjc.2021.06.005

Tian Z, Li L, Li X, Wang J, Zhang Q, Li Z, et al. Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial. JAMA Cardiol [Internet]. 2023; Available from: doi:10.1001/jamacardio.2023.3030

Heitner SB, Jacoby D, Lester SJ, Owens A, Wang A, Zhang D, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy a clinical trial. Ann Intern Med [Internet]. 2019;170(11):741–8. Available from: doi:10.7326/M18-3016

Saberi S, Cardim N, Yamani M, Schulz-Menger J, Li W, Florea V, et al. Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis. Circulation [Internet]. 2021;143(6):606–8. Available from: doi:10.1161/CIRCULATIONAHA.120.052359